Aridis Pharmaceuticals CEO Invited to Speak on Infectious Disease Panel at 2016 Anti-Infectives Rx Conference

SAN JOSE, Calif., September 21, 2016 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that CEO Vu Truong, Ph.D., will participate on a panel at the 2016 Anti-Infectives Rx Conference, held September 21, 2016, and hosted by Boston Biotech Conferences.

 

Event Details

Panel: Breakthroughs in Infectious Disease Programs
Date: September 21, 2016
Time: 4:10 p.m. – 4:40 p.m. (Eastern Time)
Location: Harvard Medical School-Joseph B. Martin Conference Center, Boston

 

Dr. Truong will be joined by fellow panelists Chip Clark, CEO and President of Genocea; David Huang, CMO of MotifBio; Larry Kauvar, Chief Scientist of Trellis Bioscience; and Ankit Mahadevia, CEO of Spero Therapeutics.  The panel will be moderated by Jeffrey Moore, President of MP Healthcare.

 

About Aridis Pharmaceuticals, Inc.

Aridis is a privately held biopharmaceutical company applying its proprietary monoclonal antibody discovery technology MabIgXTM to produce novel infectious disease focused therapies.  Aridis’ product pipeline includes AR-101 (AerumabTM) anti-Pseudomonas aeruginosa LPS human monoclonal antibody; AR-301 (SalvecinTM) anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AerucinTM, a broadly reactive anti-Pseudomonas aeruginosa human monoclonal antibody initially being developed to treat acute pneumonia; PanaecinTM, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

 

Contacts:

 

Tiberend Strategic Advisors, Inc.
Joshua E. Drumm, Ph.D. (investors)
jdrumm@tiberend.com
(212) 375-2664

 

Andrew Mielach (media)
amielach@tiberend.com
(212) 375-2694